News

CMN Weekly (24 February 2023) - Your Weekly CRISPR Medicine News

Some of the best links we picked up around the internet

By: Gorm Palmgren - Feb. 24, 2023

Top picks

Research

Industry

Detection

Reviews

News from CRISPR Medicine News

  • Monday, we reported on a novel CRISPR-Cas13d therapy for Huntington’s disease developed by Johns Hopkins and University of California San Diego researchers. Huntington's disease is fatal, and despite decades of research, there is no known cure. The new approach, however, uses Cas13d to deplete cells for the mutant mRNA transcripts that contribute to the pathogenesis of the disease.

To get more of the CRISPR Medicine News delivered to your inbox, sign up to the free weekly CMN Newsletter here.

Tags

HashtagArticleHashtagMissing linksHashtagNewsHashtagCMN Weekly

News: CMN Weekly (24 February 2023) - Your Weekly CRISPR Medicine News
CLINICAL TRIALS
Solid Tumors (NCT03970382)
Sponsors:
PACT Pharma, Inc.
Indicator
IND Enabling
Phase I
Phase II
Phase III
Beta-Thalassemia, BT, (NCT05442346)
Sponsors:
Bioray Laboratories
IND Enabling
Phase I
Phase II
Phase III
IND Enabling
Phase I
Phase II
Phase III
View all clinical trials
close
Search CRISPR Medicine